An appropriate candidate for ibogaine ceremony is someone with a documented problem that conventional approaches have not resolved, who clears the medical screening, and who is prepared to do the work the experience makes possible. Ibogaine does not perform well for people who arrive with light curiosity, acute psychiatric instability, or the expectation that ceremony replaces sustained effort.
The medical screening determines physical safety. The intake conversation determines fit. These are not the same assessment, and passing the first does not guarantee passing the second.
Key facts
- Iboga ceremony at Transcend: $2,000–$5,000 CAD; on-site physician, ECG monitoring, facilitation, 2–3 day recovery included
- Required before any ceremony: 12-lead EKG, blood panel (liver/kidney/CBC), full medication review, psychiatric history
- Absolute contraindications: QT prolongation, current SSRIs/SNRIs without supervised taper, lithium, active psychosis, severe liver or kidney disease, pregnancy
- 5-MeO-DMT ceremony: $600–$1,500 CAD; same screening requirements apply
- Every application receives a personal response within 2–3 business days
What the medical screening actually determines
The pre-ceremony screening is not a formality. It exists because ibogaine has real physiological effects that make certain medical conditions absolute disqualifiers—and because those conditions are not always apparent without testing.
The 12-lead EKG screens for QT prolongation. Ibogaine prolongs the QT interval—the cardiac electrical cycle—and administering it in someone who already has a prolonged QT or significant arrhythmia creates conditions for fatal cardiac events. This is the reason an on-site physician and continuous ECG monitoring are standard practice during ibogaine ceremony, not optional extras. The pre-ceremony EKG identifies this risk before ceremony, not during it.
The blood panel checks liver function, kidney function, and a complete blood count. Ibogaine is metabolized by the liver; severe liver disease is an absolute contraindication, and meaningfully compromised liver function requires evaluation. Kidney function and CBC are standard inputs. These are the same tests any GP can order. The results are reviewed before any ceremony date is confirmed.
The medication review checks for specific interactions. SSRIs and SNRIs are absolute contraindications—not managed, not tapered informally, not used at low dose. They require full physician-supervised clearance before ceremony is possible. Lithium is an absolute contraindication with no exception. Methadone requires a specific clinical transition protocol. The review catches these before a date is confirmed, not after.
The psychiatric history assessment looks at stability, not diagnosis. A history of depression or anxiety does not disqualify. Active psychosis or a schizophrenia-spectrum disorder is an absolute contraindication. Acute psychiatric crisis within a clinically relevant period before ceremony is a reason to wait. Ibogaine amplifies what is present. It does not stabilize what is acutely unstable.
What the screening cannot tell you is whether ibogaine is the right intervention for your specific situation. That question is addressed in the intake conversation—which is where candidacy, timing, and programme structure are discussed directly.
The positive indicators for ibogaine candidacy
The clearest positive indicator is a documented history with conventional treatment. The people who typically benefit most from ibogaine ceremony are those who have genuinely tried the standard interventions—medication, therapy, structured programmes—and found them insufficient. Not tried one antidepressant for six weeks and abandoned it. Actually exhausted the reasonable prior options.
Specific presentations where ibogaine has the strongest evidence base:
- Opioid dependence.The neurological reset ibogaine produces is most direct for opioid use disorder. Ibogaine interrupts opioid receptor function and upregulates GDNF—glial cell line-derived neurotrophic factor—in dopaminergic midbrain pathways. The reduction in craving immediately after ceremony is documented across the clinical literature. Whether it produces lasting change depends on what follows.
- Treatment-resistant depression and PTSD. The Stanford study published in Nature Medicine in February 2023 documented an average 87% reduction in depression symptoms and 88% reduction in PTSD symptoms at one month in 30 special operations veterans—a population that had already tried conventional treatment. For context: conventional antidepressant research considers a 50% reduction in depression scores a strong response.
- Conditions driven by unresolved trauma.Ibogaine tends to produce a biographical review during the active experience—12–24 hours during which specific memories and patterns surface with unusual clarity. People with conditions rooted in unresolved trauma often describe ibogaine as doing in one night what years of conventional therapy did not. Whether that description reflects genuine processing or post-hoc narrative depends on what integration follows.
A secondary positive indicator is practical readiness. The ceremony takes 12–24 hours of active experience. Recovery takes 2–3 days. The neuroplasticity window—the period during which noribogaine remains biologically active and new patterns are more accessible—lasts weeks to months after a flood dose. Someone who cannot clear a full week around ceremony is not in a position to use what the experience makes possible, regardless of whether the medical picture supports proceeding.
Integration support in place before ceremony is a positive indicator, not a recommendation. The ceremony opens the window. Arriving with a structure to use that window—integration coaching, a cleared schedule, specific commitments—is materially different from arriving and figuring it out afterward. See what integration coaching involves for the structure of that support and how it works alongside ceremony.
The psychological position that produces results
The people who come to ibogaine ceremony with the strongest outcomes are often the ones who spent years trying everything else first. SSRIs that blunted rather than resolved. Therapy that circled without landing. Abstinence-based programmes that held for months, then didn't.
By the time they arrive, they are not naive about the difficulty of what they are attempting. They have evidence that the other approaches are not enough. That scepticism—earned the hard way—tends to produce people who are genuinely ready to encounter what ibogaine shows them, rather than what they hoped it would show them. The two are often not the same.
Ibogaine is not the medicine for people who want to skip the work. The Stanford study documented what practitioners had been observing for years: that ibogaine produces changes in populations who had already tried everything else—88% reduction in PTSD symptoms in veterans who were not naive about what treatment looks like. The medicine worked. It worked in people who came with evidence that conventional approaches were not sufficient, not in people who arrived hoping for an easier path.
The person who arrives with a strong emotional case for why they should be an exception to the preparation requirements, or who is primarily seeking the intensity of the experience rather than the change the experience makes possible, tends to encounter a different ceremony than the one they expected. Ibogaine shows people what they have been avoiding. That is not what people seeking a shortcut to insight are looking for.
What this is not
Ibogaine ceremony is not a spiritual vacation. It is not a way of feeling something profound without the work of sustained change. People who arrive with those intentions encounter the experience as it is—not as they hoped it would be—and leave disappointed, which is a different outcome from the one they expected but may still be instructive.
It is not the right intervention for someone who has not genuinely tried prior approaches. A first-line treatment for depression or anxiety is not ibogaine. The evidence base for ibogaine is built on treatment-resistant presentations—conditions where the standard interventions were applied and insufficient. The established treatment landscape exists for good reasons, and bypassing it is not a sign of readiness.
It is also not a cure for addiction. See ibogaine and relapse for what the mechanism actually does and why relapse after ceremony is a post-ceremony problem, not a ceremony failure. The window closes. What determines the outcome is what happens in the weeks the window is open.
Integration is not optional. A ceremony without integration support is not a complete programme—it is access to a compound. The integration period is where the neuroplasticity window is used. Providers who hand people a pamphlet and wish them luck are not offering ibogaine treatment. They are offering ibogaine.
Who is not an appropriate candidate
Absolute contraindications. These cannot be resolved by preparation effort:
- QT prolongation or significant cardiac arrhythmia on a baseline EKG
- Recent myocardial infarction
- Severe liver or kidney disease
- Active psychosis or schizophrenia-spectrum disorder
- Lithium—no exception, no transition protocol
- Pregnancy
Contraindications requiring specific protocols before ceremony is possible:
- Current SSRIs or SNRIs—require full physician-supervised taper to clearance; fluoxetine requires 4–6 weeks after the final dose; shorter-acting SSRIs clear in approximately 1–2 weeks under medical supervision
- Methadone—requires a specific clinical transition protocol
- Certain QT-prolonging medications—require physician review before proceeding
People who are not appropriate candidates right now, regardless of the long-term picture:
- Someone in acute psychiatric crisis or acute psychiatric instability
- Someone with active substance use who has not addressed the pre-ceremony detox question with the provider
- Someone who cannot commit to the full recovery period—2–3 days immediately following ceremony, with nothing scheduled
- Someone with no integration support in place and no plan to build any
Any provider offering ibogaine to someone without a completed EKG is not operating with appropriate safety infrastructure. The cardiac screen is not optional—it is the difference between identifying QT prolongation before ceremony and encountering it during. Providers who skip it are cutting costs at the expense of the person in the chair. This applies regardless of how the provider describes their programme.
The cardiac safety literature on ibogaine is consistent on this point: QT-related cardiac events in ibogaine settings occur in people whose screening was inadequate or absent. The pre-ceremony EKG exists to prevent this.
Is this right for you?
If the clinical picture fits—a treatment-resistant condition, a completed medical screen, the capacity to do the integration work—the application is the next step. The intake conversation addresses your specific situation directly. Every application receives a personal response within 2–3 business days.
If you are not sure whether the clinical picture fits, the application is still the right starting point. The screening conversation determines candidacy. It is not designed to find reasons to say no—it is designed to determine whether ceremony is appropriate for you specifically, and if so, what the programme requires.